Use of stimulants for attention deficit hyperactivity disorder: FOR

BMJ

Volumn 329, Issue 7471, 2004, Pages 907-

  Coghill, David ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; ANTIHISTAMINIC AGENT; CISAPRIDE; DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DIFFERENTIAL DIAGNOSIS; HUMAN; RISK FACTOR; TREATMENT OUTCOME; CARDIOTOXICITY; CRYING; INSOMNIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 7044252849     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.329.7471.907     Document Type: Article

References (10)

1. Taylor E, Chadwick O, Heptinstall E, Danckaerts M. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry 1996; 35: 1213–1226.
2. Castellanos FX, Swanson J. Biological underpinnings of ADHD. In: Sandberg S, ed. Hyperactivity and attention disorders in childhood Cambridge: Cambridge University Press, 2002: 336–366
3. Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, et al. The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Can J Psychiatry 1999; 44: 1025–1035.
4. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord 2002; 6(suppl 1): S65–S71.
5. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999; 56: 1073–1086.
6. Scottish Intercollegiate Guidelines Network. Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Edinburgh: SIGN, 2001.
7. National Institute for Clinical Excellence. Guidance on the use of methylphenidate for attention deficit/hyperactivity disorder (ADHD) in childhood. SIGN Technology appraisal guideline No 13. www.nice.org.uk/page.aspx?o=11652 (accessed 15 Sep 2004).
8. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(suppl 2): 26–49S.
9. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033–1044.
10. Taylor E, Sergeant J, Doepfner M, Buitelaar J, Rothenberger A, Zuddas A, et al. Clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004; 13(suppl 1): I7–30.